ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis

-0.24 (-2.82%)
(As of 04/24/2024 ET)
Today's Range
50-Day Range
52-Week Range
334,673 shs
Average Volume
612,058 shs
Market Capitalization
$797.09 million
P/E Ratio
Dividend Yield
Price Target

ARS Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
124.0% Upside
$18.50 Price Target
Short Interest
13.13% of Float Sold Short
Dividend Strength
News Sentiment
0.32mentions of ARS Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$8.92 M Bought Last Quarter
Proj. Earnings Growth
From ($0.69) to ($0.34) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.94 out of 5 stars

Medical Sector

376th out of 909 stocks

Pharmaceutical Preparations Industry

166th out of 423 stocks

SPRY stock logo

About ARS Pharmaceuticals Stock (NASDAQ:SPRY)

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

SPRY Stock Price History

SPRY Stock News Headlines

Exposed: 10 CENT Crypto to Explode April 20th?
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
Exposed: 10 CENT Crypto to Explode April 20th?
Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than Bitcoin
ARS Pharma Submits Addl. Data In Response To FDA's CRL For Neffy
ARS Pharmaceuticals just upgraded at Leerink, here's why
See More Headlines
Receive SPRY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for ARS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Price / Sales
Book Value
$2.40 per share


Free Float
Market Cap
$797.09 million
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. Richard Lowenthal M.B.A. (Age 58)
    M.S., MSMSEL, Founder, President, CEO & Director
    Comp: $908.83k
  • Dr. Sarina Tanimoto M.B.A. (Age 56)
    M.D., Co-Founder & Chief Medical Officer
    Comp: $748.97k
  • Mr. Eric Karas (Age 52)
    Chief Commercial Officer
    Comp: $618.61k
  • Dr. Robert Bell Ph.D.
    Co-Founder & Chief Science Officer
  • Ms. Kathleen D. Scott CPA
    Chief Financial Officer
  • Mr. Brian T. Dorsey M.S. (Age 55)
    Chief Operations Officer
  • Mr. Alexander A. Fitzpatrick Esq. (Age 57)
    Chief Legal Officer & Secretary
  • Mr. Daniel Relovsky
    Senior Vice President of Marketing
  • Mr. Harris Kaplan M.B.A. (Age 72)
    Executive Vice President of Commercial Strategy
  • Mr. Justin Chakma (Age 34)
    Chief Business Officer & Secretary

SPRY Stock Analysis - Frequently Asked Questions

Should I buy or sell ARS Pharmaceuticals stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ARS Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SPRY shares.
View SPRY analyst ratings
or view top-rated stocks.

What is ARS Pharmaceuticals' stock price target for 2024?

4 equities research analysts have issued 12 month price objectives for ARS Pharmaceuticals' stock. Their SPRY share price targets range from $18.00 to $19.00. On average, they anticipate the company's stock price to reach $18.50 in the next year. This suggests a possible upside of 124.0% from the stock's current price.
View analysts price targets for SPRY
or view top-rated stocks among Wall Street analysts.

How have SPRY shares performed in 2024?

ARS Pharmaceuticals' stock was trading at $5.48 at the beginning of 2024. Since then, SPRY shares have increased by 50.7% and is now trading at $8.26.
View the best growth stocks for 2024 here

Are investors shorting ARS Pharmaceuticals?

ARS Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 5,500,000 shares, an increase of 29.4% from the March 15th total of 4,250,000 shares. Based on an average trading volume of 643,600 shares, the short-interest ratio is currently 8.5 days. Approximately 13.1% of the shares of the company are short sold.
View ARS Pharmaceuticals' Short Interest

When is ARS Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our SPRY earnings forecast

How were ARS Pharmaceuticals' earnings last quarter?

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) posted its quarterly earnings results on Thursday, March, 21st. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.07.

How do I buy shares of ARS Pharmaceuticals?

Shares of SPRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SPRY) was last updated on 4/24/2024 by Staff

From Our Partners